Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Zhenzhou, China Clinical Trials

A listing of Zhenzhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma

Phase

0.0 miles

Learn More »

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Primary Objectives To determine the feasibility ad safety of BCMA CAR-T cells in treating patients with multiple myeloma. To determine in vivo dynamics and persistency of BCMA CAR-T cells. To access the efficacy of BCMA CAR-T cells in patients with multiple myeloma. Secondary Objectives To assess the bone marrow and …

Phase

0.0 miles

Learn More »

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory diffuse Non-Hodgkin lymphoma. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Follow-up, and Survival …

Phase

0.0 miles

Learn More »

A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors

This is an open label, dose escalation phase I study to evaluate the clinical safety, tolerability in subjects with advanced solid tumors, and to establish the Maximum Tolerated Dose (MTD#, if any). This study is composed of two dose level: 1 and 3 mg/kg.

Phase

0.0 miles

Learn More »

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, multiple-ascending dose trial. Study consists of dose-escalation part in subjects with metastatic or locally advanced solid tumors, and expansion part with selected indications.

Phase

0.0 miles

Learn More »

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Primary Objectives To determine the feasibility ad safety of anti-CD19/ CD22 CAR-T cells in treating patients with CD19-positive Acute Lymphoblastic Leukemia. Secondary Objectives To determine in vivo expression, dynamics and persistency of anti-CD19/CD22 CAR-T cells. To determine in vivo expression of CD19-positive B cells. To access the complete remission rate …

Phase

0.0 miles

Learn More »

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions

This is a single-center, open-label, non-randomized, parallel-controlled Phase I clinical study carried out in subjects with varying degrees (mild or moderate) of renal impairment, and age-, weight-, and gender-matched subjects with normal renal functions.

Phase

0.79 miles

Learn More »

CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia

This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia. And to evaluate the pharmacokinetics of CD7 CAR-T cells in patients.

Phase

2.42 miles

Learn More »

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Although CAR19 T cell therapy brings hope, the patients with refractory/relapsed B-cell lymphoma is still a problem for the current treatment. There are still some patients with poor therapeutic efficacy, and the efficacy of CAR19-T cell therapy remains to be improved. Basic research shows that there is a synergistic effect …

Phase

2.42 miles

Learn More »

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

This is a multicentre single arm clinical trial conducted in China.The purpose of this study is to evaluate and observe Anlotinib (12mg,QD, PO d1-14, 21 days per cycle) combined with Pemetrexed(500mg/m2,IV,d15-21,21 days per cycle)and Carboplatin(AUC5,IV,d15-21,21 days per cycle,4 cycles) as the first-line treatment in patients with advanced nonsquamous NSCLC .After …

Phase

2.42 miles

Learn More »